Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study

Trial Profile

Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Liver cirrhosis; Thrombosis
  • Focus Therapeutic Use
  • Acronyms Childbenox
  • Most Recent Events

    • 16 Jun 2016 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.
    • 16 Jun 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Jul 2019.
    • 08 Oct 2015 Planned End Date changed from 1 Apr 2019 to 1 Jun 2019, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top